Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
assessment, by CEUS, of early response to antiangiogenic treatment in patients with liver mets from colorectal cancer treated by Bevacizumab plus Folfiri every 14 days (or by other protocols including 5FU and Irinotecan plus bevacizumab). Aim: Early assessment of the antiangiogenetic effectiveness of bevacizumab studied by CEUS vs RECIST criteria. Theﾓtargetﾔ lesions are only the ones measurable and the ones susceptible of reiterable measuring in CEUS. After US identification of a ﾓtargetﾔ lesion the microcirculation of which will be evaluated by CEUS.
Critère d'inclusion
- methastatic colorectal cancer